Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
about
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisBiomarkers in Exhaled Breath Condensate Are Not Predictive for Pulmonary Exacerbations in Children with Cystic Fibrosis: Results of a One-Year Observational StudyProbiotic supplementation in children with cystic fibrosis-a systematic review.Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosisExome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosisMeasuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyRecent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosisInhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis.Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomesThe prevalence of clinical features associated with primary ciliary dyskinesia in a heterotaxy population: results of a web-based survey.Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.Tackling the increasing complexity of CF care.Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas aeruginosa infection in children with cystic fibrosis.Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.Mixed bacterial-fungal infections in the CF respiratory tract.Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis.Data that empower: The success and promise of CF patient registries.Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.Clinician's Commentary on Morgan et al.(1).Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.Differential geographical risk of initial Pseudomonas aeruginosa acquisition in young US children with cystic fibrosis.Residual Weighted Learning for Estimating Individualized Treatment Rules.Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls.Variation in Cilia Protein Genes and Progression of Lung Disease in Cystic Fibrosis.Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.
P2860
Q24188054-E9985F9D-E2F0-426C-9BD5-DC872595A0A7Q24202879-2B9F79BE-EFEC-4702-A36B-71180243F1B4Q26471106-544C7544-8930-4DC1-B3C6-9E2EB6B71E69Q28551208-C8C8FE3D-6CFF-496C-AD39-3037883693FFQ30248234-9D0AAB40-8720-4AEF-987D-4BA425015BFEQ30352400-E4EA3D8B-5981-4782-B2D4-F9AF11455231Q30401897-E8878FAE-064E-4394-817C-87B56500DFD6Q30412485-210F16F6-2721-4B7C-8428-B6D761A9D4D4Q30413773-8D25B3C2-CFDA-4B15-AE9D-A3E86AEC0F89Q30422695-59E1EDFD-2884-43F6-A9B0-CACFC8E13755Q30452653-4DD1CFD1-2EF9-465B-B6E4-055222E183AAQ33697276-6CAFB46C-6CAF-48D9-8F97-AF95E29D4134Q33862073-C92DB1A3-10EC-4992-821C-18715720B2C4Q34275485-0FFDF9E5-9AD0-4BC2-BBFA-472E9565AD5CQ34422248-84233A90-C456-415E-9887-E12159DDFDB9Q34480377-C2F5C0A8-0F65-413C-9CFB-B9B7708C3BFDQ35206397-3D9EECA6-E144-4581-9FF9-3D6ED2B7025EQ35654397-E3115135-675F-4D73-804B-212A9602C7F5Q36034488-B2DECE68-59F5-438B-9936-68CD8ACD9921Q36226940-B9AA132E-CE3C-4846-BDBD-C5C2D3DB1C70Q36446781-14CBB71F-E181-4DCD-9E69-29AE7336B4C9Q36673569-21B7912C-E3CB-41F4-BCB1-853E3B864A7FQ37440612-4A9CC269-648A-4A32-A4E2-835E32E48D81Q37628124-323636D2-814E-4B80-811C-B8ADE3E63194Q37727308-471AE7C0-37FB-4371-AC89-7C5CB2C06729Q37775620-B4A36F11-2EC9-4498-8EF2-F31AD3844C26Q37808469-D9256AD6-9C16-4C27-A9C8-79917039574FQ38101836-8094AD0C-007F-4363-AB8C-9FFB4F5CDDA2Q38821019-D3EAA57C-8DC6-416B-B9AE-1B98EA4555F0Q39017682-B98CFBA1-3EEB-4C9B-9CED-07EB0E0D1BD6Q40041155-0FC7DB66-CE7C-48BE-A38F-B282E6F27443Q42011378-522C08A6-39E3-4DB7-A821-7C407B18B854Q42241705-88270074-F694-468F-A083-BE60084E6016Q42908875-65741C18-AACC-471C-B52F-E9EB59E6BA89Q44272126-27F5F213-6125-4A6E-AA4B-6A94D34BB3EEQ44656924-4CCC41DD-AF79-423B-A25D-D88796F7B181Q45945490-73A4F04B-9981-4628-A055-52D9D3EF900BQ47701149-4E13A97D-CE6E-4C53-99C9-57A7D2B96A8DQ50090344-0BFF1120-9384-4F0D-96BC-11F5B2CE7BB1Q55437809-81367213-4ECD-4F16-8BA0-60BEE87A56B9
P2860
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Early anti-pseudomonal acquisi ...... trial and observational study'
@ast
Early anti-pseudomonal acquisi ...... trial and observational study'
@en
type
label
Early anti-pseudomonal acquisi ...... trial and observational study'
@ast
Early anti-pseudomonal acquisi ...... trial and observational study'
@en
prefLabel
Early anti-pseudomonal acquisi ...... trial and observational study'
@ast
Early anti-pseudomonal acquisi ...... trial and observational study'
@en
P2093
P2860
P1476
Early anti-pseudomonal acquisi ...... trial and observational study'
@en
P2093
Bonnie W Ramsey
EPIC Study Group
George Retsch-Bogart
Judy Williams
Julia Emerson
Margaret Rosenfeld
Miriam M Treggiari
Nicole Mayer-Hamblett
Richard A Kronmal
Ronald L Gibson
P2860
P304
P356
10.1016/J.CCT.2009.01.003
P407
P577
2009-01-15T00:00:00Z